C1ORF112 drives lung adenocarcinoma progression through e2f8-mediated transcriptional activation

Read full text
Authors: JingSi Wang, Guixue Yang, X M Deng, Xiaobing Liu, Dan Chen, QuanXing Liu
Cited by: 1

Abstract

Background: Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality, with poor prognosis driven by metastasis and therapeutic resistance. Chromosome 1 open reading frame 112 (C1ORF112) encodes a nuclear protein involved in DNA replication and repair, but its role in LUAD is unclear. To systematically investigate the clinical relevance, functional impact, and transcriptional regulation of C1ORF112 in LUAD through integrative bioinformatic and experimental approaches. Methods: C1ORF112 expression and prognostic significance were analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Single-cell RNA sequencing defined cellular localization and communication patterns. Functional enrichment, protein-protein interaction (PPI), and transcription factor prediction analyses were performed. In vitro assays and xenograft models assessed biological functions and transcriptional regulation by E2F8. Results: T cells. Overexpression of C1ORF112 inhibited apoptosis and promoted proliferation in LUAD cells, while xenografts exhibited accelerated tumor growth and increased Ki67 expression. Mechanistically, E2F8 directly bound the C1ORF112 promoter, enhancing its transcription and inhibiting downstream p53 signaling. Conclusions: Our integrative analysis suggests that C1ORF112 exhibits oncogenic properties in LUAD by promoting tumor survival, proliferation, and potentially remodeling the tumor microenvironment. The transcriptional activation by E2F8 highlights the E2F8-C1ORF112 axis as a candidate prognostic biomarker and therapeutic vulnerability, though prospective clinical validation and drug sensitivity studies are warranted.

Fields of Study & Subjects

Ferroptosis and cancer prognosis Single-cell and spatial transcriptomics Chromatin Remodeling and Cancer

Publication details

Journal / source
Journal of Thoracic Disease
Publisher
AME Publishing Company
Volume
18
Issue
6
Pages
606–606
Publication date
1 June 2026
Language
EN